Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Boehringer

Eli Lilly HQ

Surging Trulicity takes sting out of Lilly’s arthritis setback

First quarter sales of the diabetes treatment were up by 160%, exceeding analysts predictions

- PMLiVE

FDA won’t add outcomes data to Januvia label

Merck & Co’s application rejected despite TECOS outcomes data

AstraZeneca AZ

AZ data suggest SGLT2 inhibitors can reduce heart failure risk

Publishes real-world data for study involving Forxiga/Farxiga, Invokana and Jardiance

Sanofi to develop a mobile app for insulin patients

Will work with therapeutic companion software company Voluntis

- PMLiVE

Type 2 diabetes can be reversed in just four months, say researchers

A controlled diet and a strict exercise regime could help cure type 2 diabetes

- PMLiVE

Merck & Co and Pfizer take aim at diabetes with trio of new drugs

File ertugliflozin-based products with EU and US regulators

- PMLiVE

AZ gets US approval for diabetes combo Qtern

Wins licensing for Onglyza/Farxiga dual-therapy after rejection by the FDA in 2015

- PMLiVE

Novo Nordisk invests £115m in Oxford diabetes unit

But Danish pharma company admitted Brexit had made it a harder decision

- PMLiVE

Lilly pilots enhanced online trial information

Company aims to aid comprehension of the informed consent process

- PMLiVE

J&J pondering future of diabetes device assets

Three diabetes care subsidiaries under review as firm forecasts measured 2017 sales

Eli Lilly HQ

Lilly to buy migraine drug developer CoLucid for $960m

Deal revolves around lasmiditan, which the firm out-licensed in 2005

Novo signs personalised digital health deal in diabetes

Will work with Glooko on jointly-developed and branded solutions

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links